PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

314 articles indexed across 20 specialties, each reviewed by a licensed pharmacist before publication.

Showing all 314 articles.Sort: Newest | Oldest
Mirikizumab sustains multidomain UC remission through four years
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Sands BE, Clemow DB, D'Haens G, et al.
Jun 1, 2026 · Published in: Inflammatory Bowel Diseases

Four-year study shows lasting ulcerative colitis remission with mirikizumab.

ESC and EACTS Issue Consensus on Antithrombotic Therapy After CABG
Consensus Statement Cardiology / Anticoagulation Inconclusive Grade: Low
Sandner S, Gaudino M, Agewall S, et al.
May 21, 2026 · Published in: European Heart Journal

Balance risks: Antithrombotic therapy post-bypass under scrutiny.

Daraxonrasib Shows Early Activity in RAS-Mutated Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wolpin BM, Park W, Garrido-Laguna I, et al.
May 7, 2026 · Published in: The New England Journal of Medicine

Daraxonrasib shows promise in advanced RAS-mutated pancreatic cancer.

Semaglutide cuts heavy drinking in alcohol use disorder with obesity
Analysis Behavioral Health / Addiction Medicine Hypothesis-generating Grade: Moderate
Klausen MK, Justesen SK, Pedersen JN, et al.
May 2, 2026 · Published in: Lancet

Semaglutide reduces alcohol intake in comorbid obesity.

AASLD Adds Semaglutide to MASH Practice Guidance With NIT-Based Selection
Guideline Gastroenterology / Hepatology Practice-changing Grade: Moderate
Bansal MB, Patton H, Morgan TR, et al.
May 1, 2026 · Published in: Hepatology (Baltimore, Md.)

Semaglutide offers new hope for MASH management with significant fibrosis improvement.

Asundexian Cuts Recurrent Stroke Without Excess Bleeding
Analysis Cardiology / Anticoagulation Practice-changing Grade: High
Sharma M, Dong Q, Hirano T, et al.
Apr 16, 2026 · Published in: N Engl J Med

Could a new anticoagulant improve stroke prevention?

KRAS Inhibitors May Unlock Immunotherapy in Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Stanger BZ, Vonderheide RH
Apr 15, 2026 · Published in: Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

KRAS inhibitors may revolutionize immunotherapy for pancreatic cancer.

Surviving Sepsis Campaign 2026 Guidelines Overhaul Adult Sepsis Management
Guideline Critical Care / ICU Practice-changing Grade: Moderate
Prescott HC, Antonelli M, Alhazzani W, et al.
Apr 1, 2026 · Published in: Crit Care Med

2026 sepsis guidelines enhance antimicrobial and fluid strategies.

Atezolizumab Plus FOLFOX Halves Recurrence in dMMR Stage III Colon Cancer
Analysis Oncology Pharmacy Practice-changing Grade: High
Sinicrope FA, Ou FS, Arnold D, et al.
Mar 26, 2026 · Published in: N Engl J Med

Atezolizumab enhances survival in dMMR colon cancer.

Obinutuzumab Improves Response in Active Non-Renal SLE
Analysis Rheumatology / Immunology Practice-changing Grade: High
Furie RA, Dall'Era M, Vital EM, et al.
Mar 6, 2026 · Published in: N Engl J Med

Obinutuzumab improves SLE outcomes in the recent ALLEGORY trial.

Biomarker Strategies for Chemotherapy Cardiotoxicity: Promise Versus Validation
Analysis Oncology Pharmacy Confirmatory Grade: Very Low
Kong Y, He R, He H, et al.
Feb 25, 2026 · Published in: Rev Cardiovasc Med

New biomarkers offer promise for early detection of chemotherapy-induced heart damage.

Plasma p-tau217 Clocks Estimate Timing of Alzheimer Symptom Onset
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Moderate
Feb 19, 2026 · Published in: Nature Medicine

This work demonstrates that a single blood-based %p-tau217 measurement can estimate not only whether but approximately when a cognitively unimpaired person will develop symptomatic Alzheimer disease, with implications for how pharmacists interpret emerging blood biomarker tests and screen for anti-amyloid therapy candidates.

ADA Standards of Care: Pharmacologic Treatment of Obesity in Adults
Guideline Obesity / Weight Management Practice-changing Grade: Moderate
American Diabetes Association Professional Practice Committee for Obesity
Jan 13, 2026 · Published in: BMJ Open Diabetes Res Care

The ADA's new Obesity Association guideline reframes obesity pharmacotherapy around treating obesity-related diseases rather than weight targets alone, elevates GLP-1RA and dual GIP/GLP-1RA agents to preferred status across multiple comorbidities, and mandates indefinite continuation to prevent weight recurrence.

Resmetirom Update: Positioning the First Approved MASH Therapy
Analysis Gastroenterology / Hepatology Confirmatory Grade: Moderate
Van Kleef LA, Michel M, Alkhouri N, et al.
Jan 1, 2026 · Published in: Drug Design, Development and Therapy

Resmetirom is the first drug to reverse MASH and fibrosis.

Active Pharmacist Ward Integration Outperforms Education in Renal Prescribing
Analysis Medication Safety Hypothesis-generating Grade: Low
Özmen Ö, Bektay MY, Karatoprak C, et al.
Jan 1, 2026 · Published in: Quasi-Experimental Study

Pharmacist interventions cut drug-related issues by 30% in renal patients.